Inmed provides update on baymedica rare cannabinoid business

$2.3m revenues (unaudited) in q4 2023, representing 123% increase quarter over quarter ("qoq") optimized and scaled up manufacturing processes over the last 12 months to meet increasing demand third consecutive quarter with significant revenue growth vancouver, british columbia--(newsfile corp. - july 20, 2023) - inmed pharmaceuticals inc. (nasdaq: inm) ("inmed"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today provided a commercial and manufacturing update on its subsidiary baymedica llc ("baymedica"), a leading supplier of bioidentical rare cannabinoids to the health and wellness ("h&w") market. "we are very encouraged to see another strong quarter with (unaudited) revenues in excess of $2.3m, representing our third consecutive quarter with significant revenue growth," said eric a.
INM Ratings Summary
INM Quant Ranking